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Background Controversy remains to whether the combination of clopidogrel and proton pump inhibitors (PPI) associated with diminished 
antiplatelet effect causes reduced clinical effect of clopidogrel. This prompted us to analyze the risk of adverse cardiovascular (CV) outcomes related 
to the concomitant use of PPI and clopidogrel in an unselected population of patients with prior myocardial infarction (MI).
Methods Consecutive patients hospitalized with first-time MI between 2001 and 2007 and subsequent use of clopidogrel and PPI after discharge 
was identified by individual-level-linkage of administrative registers. The risk of CV death, MI or stroke associated with use of PPI was studied by 
propensity score matched Cox-regression models and Kaplain-Meier analysis. Follow up was one year.
Results 56774 patients were included in the study; 9167 experienced MI, CV death or stroke. 28237 (49.7%) of the patients received clopidogrel 
and 5723 (20.3%) of these received PPI. For use of PPI in combination with clopidogrel the hazard ratio (HR) and 95% confidence intervals for CV 
death, MI or stroke was 1,27 (1,15 to 1,40) while the HR for the use of PPI in patients not receiving clopidogrel was 1,14 (1,06-1,22) (Figure 1). 
There was no difference between the different subtypes of PPI.
Conclusion In patients with MI, PPI use is associated with increased cardiovascular risk independent of concomitant 
use of clopidogrel. This study does not suggest a clinically significant interaction between clopidogrel and PPI.
